Emergency Contraception: Methods, Effectiveness, and Guidance for Timely Use

1. Overview

Emergency contraception (EC) refers to a set of medical interventions that can prevent pregnancy after unprotected sexual intercourse or contraceptive failure. EC is distinct from regular, ongoing contraception; it is intended for occasional, unexpected situations and must be used as soon as possible for optimal effectiveness. Health authorities, including the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), recommend that individuals have access to EC as part of comprehensive reproductive health services.

Timely use of EC can reduce the risk of unintended pregnancy by 75–89 % when taken within the recommended window. Understanding the available methods, their relative effectiveness, potential side effects, and appropriate follow‑up care empowers patients to make informed decisions and reduces the public health burden of unintended pregnancies.

2. Causes & Risk Factors

Emergency contraception is most commonly needed in the following circumstances:

• Condom breakage or slippage.
• Missed or delayed doses of a regular hormonal contraceptive method (e.g., combined oral contraceptive pill, progestin‑only pill, contraceptive patch).
• Incorrect use of a barrier method (e.g., improper insertion of a diaphragm).
• Sexual assault or non‑consensual intercourse.
• Use of a contraceptive method that does not provide adequate protection for the individual's fertility status (e.g., certain forms of fertility awareness‑based methods).

Risk factors that increase the likelihood of requiring EC include:

• Inconsistent use of regular contraception.
• Younger age groups (adolescents and emerging adults) who may have less experience with contraceptive methods.
• Limited access to reproductive health services, including cost barriers or geographic distance.
• Substance use that impairs judgment or memory regarding contraceptive use.
• History of sexual violence.

3. Signs & Symptoms

Emergency contraception is a preventive intervention; therefore, it does not treat an existing condition and does not produce disease‑specific symptoms. However, patients may experience the following common, mild side effects after taking EC:

• Nausea or mild stomach upset (often transient).
• Headache or dizziness.
• Fatigue.
• Changes in menstrual timing (earlier or later onset, heavier or lighter flow).
• Breast tenderness.

These symptoms are generally self‑limited and do not require medical treatment. Persistent vomiting, severe abdominal pain, or signs of an allergic reaction (e.g., rash, swelling, difficulty breathing) warrant prompt medical evaluation.

4. Prevention

• Consistent Use of Primary Contraception: Selecting a reliable method (e.g., IUD, implant, combined oral contraceptive) and using it exactly as prescribed reduces the need for EC.
• Dual Protection: Combining a barrier method (condom) with a hormonal method provides protection against both pregnancy and sexually transmitted infections (STIs).
• Education & Counseling: Discussing correct use of contraceptives with a healthcare provider improves adherence.
• Access to Over‑the‑Counter EC: In many jurisdictions, levonorgestrel‑based EC is available without a prescription, facilitating rapid use.
• Advance Planning: Keeping a dose of EC on hand (e.g., in a purse or locker) ensures it can be taken promptly if needed.
• Prompt Follow‑Up: After using EC, schedule a routine appointment to discuss ongoing contraceptive options and STI screening.

5. Screening & Diagnosis

Because EC is a preventive measure, the clinical encounter focuses on screening for contraindications, assessing timing, and providing counseling rather than diagnosing a disease. Key steps include:

1. Medical History Review: Identify allergies (particularly to hormonal products), current medications (e.g., enzyme‑inducing anticonvulsants), and liver disease, which may affect EC choice.
2. Pregnancy Status Assessment: If there is any doubt about an existing pregnancy, a urine or serum hCG test should be performed before EC administration, as EC is ineffective after implantation.
3. Timing Determination: Establish the interval between intercourse and presentation. Effectiveness declines with time; therefore, precise dating guides method selection.
4. Risk Evaluation for STIs: Offer testing and counseling, especially when EC is sought after unprotected intercourse.

6. Treatment Options

Three primary categories of emergency contraception are recognized by major medical guidelines:

6.1 Levonorgestrel‑Based Pills (LNG‑EC)

• Mechanism: Primarily inhibits or delays ovulation; it does not terminate an established pregnancy.
• Dosage Forms: One‑tablet 1.5 mg dose or two‑tablet 0.75 mg doses taken 12 hours apart.
• Timing: Most effective when taken within 72 hours (3 days) of unprotected intercourse; efficacy modestly declines up to 120 hours (5 days).
• Effectiveness: Reduces pregnancy risk by approximately 75–85 % when taken within the recommended window.
• Availability: Over‑the‑counter in many countries; no prescription required for adults.
• Contraindications: None specific; caution in patients with severe liver disease.

6.2 Ulipristal Acetate (UPA) – Prescription EC

• Mechanism: Selective progesterone receptor modulator that delays ovulation even when the follicle is nearing maturation.
• Dosage: Single 30 mg tablet.
• Timing: Effective up to 120 hours (5 days) after intercourse with relatively stable efficacy throughout that period.
• Effectiveness: Approximately 85–95 % reduction in pregnancy risk when used within 120 hours.
• Prescription Status: Requires a prescription in most jurisdictions, though some regions have moved to pharmacist‑authorized dispensing.
• Drug Interactions: Reduced efficacy with enzyme‑inducing medications (e.g., rifampin, certain antiepileptics).

6.3 Copper Intrauterine Device (Cu‑IUD) – Non‑Hormonal EC

• Mechanism: Copper ions create a hostile environment for sperm and may inhibit fertilization; also interferes with implantation.
• Timing: Can be inserted up to 120 hours (5 days) after unprotected intercourse; some guidelines allow insertion up to 5 days after the estimated day of ovulation.
• Effectiveness: The most effective form of EC, with failure rates less than 0.1 %.
• Additional Benefit: Provides ongoing contraception for up to 10–12 years, eliminating the need for further EC if intercourse occurs later.
• Contraindications: Active pelvic infection, unexplained vaginal bleeding, uterine anomalies that preclude IUD placement.
• Procedure: Requires a trained clinician for insertion; follow‑up visit is recommended 4–6 weeks later to confirm placement.

6.4 Choosing the Appropriate Method

Clinical decision‑making should consider the following factors:

• Time Since Intercourse: LNG‑EC is preferred if presentation is within 72 hours; UPA or Cu‑IUD are preferred after 72 hours but within 120 hours.
• Access and Cost: Over‑the‑counter LNG‑EC may be more accessible; however, insurance coverage and pharmacy availability vary.
• Future Contraceptive Needs: Patients desiring long‑term contraception may benefit from Cu‑IUD insertion.
• Medication Interactions: Patients on enzyme‑inducing drugs should be steered toward Cu‑IUD or consider UPA with awareness of reduced efficacy.
• Medical Contraindications: Liver disease, known hypersensitivity, or uterine pathology guide method selection.

7. Myths vs Facts

8. When to See a Doctor

While EC can be obtained without a prescription in many settings, professional medical evaluation is recommended in the following situations:

• Uncertainty about the timing of ovulation or the exact date of intercourse.
• Suspected pregnancy (e.g., missed period, positive home test) – EC is ineffective after implantation.
• History of severe allergic reactions to hormonal products.
• Current use of medications known to reduce EC efficacy (e.g., certain anticonvulsants, St. John’s wort).
• Desire for a copper IUD and need for insertion assessment.
• Persistent or severe side effects after taking EC (e.g., vomiting that prevents absorption, severe abdominal pain).
• Need for comprehensive contraceptive counseling or STI screening.

Conclusion

Emergency contraception is a critical component of reproductive health care, offering a safe and effective means to prevent unintended pregnancy after contraceptive failure or unprotected intercourse. Understanding the three main options—levonorgestrel pills, ulipristal acetate, and the copper intrauterine device—allows individuals and clinicians to select the most appropriate method based on timing, medical history, and future contraceptive goals. Prompt use maximizes effectiveness, and integrating EC with ongoing contraceptive planning reduces repeat reliance on emergency measures. Health professionals should provide clear, non‑judgmental counseling, address common misconceptions, and ensure timely access to these medications or devices, thereby supporting informed decision‑making and improving public health outcomes.